INS and metabolic syndrome: A recent meta-analysis of IER [5:2 and ADF] vs. CER studies amongst individuals with type-2 diabetes or the metabolic syndrome [4 studies 355 participants] concluded IER was safe in these populations and had comparable effects with CER on glycaemic control, fasting insulin and lipid profiles [51].